Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lazzarotto D, Candoni A, Filì C, Forghieri F, Pagano L, Busca A, et al. Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey. Leuk Res. 2017;53:74–81.

    Article  Google Scholar 

  2. Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118:3785–93.

    Article  CAS  Google Scholar 

  3. Shimizu H, Saitoh T, Tanaka M, Mori T, Sakura T, Kawai N, et al. Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. Leukemia. 2012;26:2469–73.

    Article  CAS  Google Scholar 

  4. Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, et al. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transpl. 2015;50:1057–62.

    Article  CAS  Google Scholar 

  5. Aoki J, Ishiyama K, Taniguchi S, Fukuda T, Ohashi K, Ogawa H, et al. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement. Biol Blood Marrow Transpl. 2014;20:2029–33.

    Article  Google Scholar 

  6. Bar M, Tong W, Othus M, Loeb KR, Estey EH. Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2015;21:546–51.

    Article  Google Scholar 

  7. Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. Int J Hematol. 2007;86:269–74.

    Article  Google Scholar 

  8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Acute Myeloid Leukemia (Version 2.2018). https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed 20 Oct 2018.

  9. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.

    Article  CAS  Google Scholar 

  10. Gunes G, Goker H, Demiroglu H, Malkan UY, Buyukasik Y. Extramedullary relapses of acute leukemias after allogeneic hematopoietic stem cell transplantation: clinical features, cumulative incidence, and risk factors. Bone Marrow Transpl. 2019;54:595–600.

    Article  Google Scholar 

  11. Yamasaki S, Yoshimoto G, Ogawa R, Aoki K, Higuchi M, Harada N, et al. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics. Ann Hematol. 2015;94:1159–65.

    Article  Google Scholar 

  12. Yamasaki S, Hirakawa A, Aoki J, Uchida N, Fukuda T, Ogawa H, et al. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. Ann Hematol. 2017;96:289–97.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We appreciate the patients and clinical staff for their participation in the study. We are very grateful to the Japanese Data Center for Hematopoietic Cell Transplantation for data management and the Clinical Research Institute of Kyushu Medical Hospital for their editorial support. This study was supported by The Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) of the Japan Agency for Medical Research and Development (AMED). We thank Edanz Group (www.edanzediting.com) for editing a draft of this manuscript.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Satoshi Yamasaki.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the Data Management Committee of the Japanese Society for Hematopoietic Cell Transplantation and the Institutional Review Board of Kyushu Medical Center. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamasaki, S., Aoki, J., Mori, J. et al. Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease. Bone Marrow Transplant 55, 249–252 (2020). https://doi.org/10.1038/s41409-019-0527-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0527-z

This article is cited by

Search

Quick links